Under construction – not a live service
Sign in
Taking people in United StatesPhase 2

A Study to Evaluate the Efficacy, Safety, and Tolerability of VIM0423 in Individuals With Isolated Dystonia

Key facts

Where
Albuquerque, Amherst, Atlanta, Aurora, Baltimore, Birmingham, Boston, Charleston, Chicago, Cincinnati, Dallas, Denver, East Lansing, Farmington Hills, Fayetteville, Gainesville, Georgetown, Houston, Irvine, Kirkland, Los Angeles, Memphis, Miami, Nashville, New York, Olney, Orlando, Overland Park, Philadelphia, Portland, Richmond, Rochester, Sacramento, Scottsdale, Spokane, St Louis, Sun City, and Vernon, United StatesSee the 41 sites
Phase
Phase 2

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 70 years old?

Source: NCT07304089, who can take part

Where in United States

  • Albuquerque, New MexicoHospital not named in the registryContact: Study DirectorTaking people
  • Amherst, New YorkHospital not named in the registryContact: Study DirectorNot yet recruiting
  • Atlanta, GeorgiaHospital not named in the registryContact: Study DirectorTaking people
  • Aurora, ColoradoHospital not named in the registryContact: Study DirectorNot yet recruiting
  • Baltimore, MarylandHospital not named in the registryContact: Study DirectorTaking people
  • Birmingham, AlabamaHospital not named in the registryContact: Study DirectorTaking people
  • Boston, MassachusettsHospital not named in the registryContact: Study DirectorTaking people
  • Charleston, South CarolinaHospital not named in the registryContact: Study DirectorTaking people
  • Chicago, IllinoisHospital not named in the registryContact: Study DirectorTaking people
  • Cincinnati, OhioHospital not named in the registryContact: Study DirectorTaking people
  • Dallas, TexasHospital not named in the registryContact: Study DirectorTaking people
  • Denver, ColoradoHospital not named in the registryContact: Study DirectorTaking people
  • East Lansing, MichiganHospital not named in the registryContact: Study DirectorTaking people
  • Farmington Hills, MichiganHospital not named in the registryContact: Study DirectorTaking people
  • Fayetteville, North CarolinaHospital not named in the registryContact: Study DirectorTaking people
  • Gainesville, FloridaHospital not named in the registryContact: Study DirectorTaking people
  • Georgetown, TexasHospital not named in the registryContact: Study DirectorTaking people
  • Houston, TexasHospital not named in the registryContact: Study DirectorTaking people
  • Houston, TexasHospital not named in the registryContact: Study DirectorTaking people
  • Irvine, CaliforniaHospital not named in the registryContact: Study DirectorTaking people
  • Kirkland, WashingtonHospital not named in the registryContact: Study DirectorTaking people
  • Los Angeles, CaliforniaHospital not named in the registryContact: Study DirectorTaking people
  • Memphis, TennesseeHospital not named in the registryContact: Study DirectorTaking people
  • Miami, FloridaHospital not named in the registryContact: Study DirectorTaking people
  • Nashville, TennesseeHospital not named in the registryContact: Study DirectorTaking people
  • New YorkHospital not named in the registryContact: Study DirectorTaking people
  • New YorkHospital not named in the registryContact: Study DirectorTaking people
  • Olney, MarylandHospital not named in the registryContact: Study DirectorTaking people
  • Orlando, FloridaHospital not named in the registryContact: Study DirectorTaking people
  • Overland Park, KansasHospital not named in the registryContact: Study DirectorTaking people
  • Philadelphia, PennsylvaniaHospital not named in the registryContact: Study DirectorTaking people
  • Portland, OregonHospital not named in the registryContact: Study DirectorTaking people
  • Richmond, VirginiaHospital not named in the registryContact: Study DirectorTaking people
  • Rochester, New YorkHospital not named in the registryContact: Study DirectorTaking people
  • Sacramento, CaliforniaHospital not named in the registryContact: Study DirectorNot yet recruiting
  • Scottsdale, ArizonaHospital not named in the registryContact: Study DirectorTaking people
  • Scottsdale, ArizonaHospital not named in the registryContact: Study DirectorTaking people
  • Spokane, WashingtonHospital not named in the registryContact: Study DirectorTaking people
  • St Louis, MissouriHospital not named in the registryContact: Study DirectorTaking people
  • Sun City, ArizonaHospital not named in the registryContact: Study DirectorTaking people
  • Vernon, ConnecticutHospital not named in the registryContact: Study DirectorNot yet recruiting

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Vima Therapeutics
Trial code
NCT07304089
Record updated
26 October 2026
Original description
Stride Dystonia is a randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of VIM0423 in individuals with isolated dystonia.Read full original descriptionShow less

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of VIM0423 in Individuals With Isolated Dystonia (Stride Dystonia)

Stride Dystonia is a randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of VIM0423 in individuals with isolated dystonia.

The main objectives of this clinical trial are to determine the following:

* Does VIM0423 therapy improve dystonia symptoms compared to placebo? * Is VIM0423 well tolerated in individuals with isolated dystonia? and * Do the therapeutic effects of VIM0423 confer improvements on daily function and quality of life?

Inclusion: Participant must be male or nonpregnant female between 18 and 70 years of age (inclusive) at Visit 1 (Screening); The participant has a clinical diagnosis of isolated dystonia with symptoms consistent with dystonia for at least one year prior to Visit 1 (Screening); has two or more body regions affected by dystonia at Visit 1 (Screening); and has been confirmed by Investigator and Enrollment Authorization Committee; The participant may be untreated with BoNT; OR if the participant is being treated with BoNT as part of their standard of care for dystonia, they must meet protocol-specified criteria; The participants must meet protocol-specified requirements for baseline scores on the BFM and CGI-S.

ClinicalTrials.gov NCT07304089